Logo image of ELTX

ELICIO THERAPEUTICS INC (ELTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ELTX - US28657F1030 - Common Stock

9.36 USD
+0.2 (+2.18%)
Last: 11/28/2025, 8:25:46 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ELTX. ELTX was compared to 533 industry peers in the Biotechnology industry. ELTX may be in some trouble as it scores bad on both profitability and health. ELTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ELTX had negative earnings in the past year.
ELTX had a negative operating cash flow in the past year.
In the past 5 years ELTX always reported negative net income.
ELTX had a negative operating cash flow in each of the past 5 years.
ELTX Yearly Net Income VS EBIT VS OCF VS FCFELTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -184.95%, ELTX is doing worse than 88.56% of the companies in the same industry.
Looking at the Return On Equity, with a value of -2977.75%, ELTX is doing worse than 82.36% of the companies in the same industry.
Industry RankSector Rank
ROA -184.95%
ROE -2977.75%
ROIC N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELTX Yearly ROA, ROE, ROICELTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELTX Yearly Profit, Operating, Gross MarginsELTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for ELTX has been increased compared to 1 year ago.
ELTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ELTX has a worse debt to assets ratio.
ELTX Yearly Shares OutstandingELTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ELTX Yearly Total Debt VS Total AssetsELTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -11.47, we must say that ELTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ELTX (-11.47) is worse than 75.23% of its industry peers.
A Debt/Equity ratio of 5.09 is on the high side and indicates that ELTX has dependencies on debt financing.
ELTX has a Debt to Equity ratio of 5.09. This is amonst the worse of the industry: ELTX underperforms 82.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.09
Debt/FCF N/A
Altman-Z -11.47
ROIC/WACCN/A
WACCN/A
ELTX Yearly LT Debt VS Equity VS FCFELTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.28 indicates that ELTX has no problem at all paying its short term obligations.
ELTX has a Current ratio of 2.28. This is in the lower half of the industry: ELTX underperforms 72.05% of its industry peers.
A Quick Ratio of 2.28 indicates that ELTX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.28, ELTX is not doing good in the industry: 69.79% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.28
ELTX Yearly Current Assets VS Current LiabilitesELTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.11% over the past year.
EPS 1Y (TTM)36.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.33% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.67%
EPS Next 2Y24.67%
EPS Next 3Y19.38%
EPS Next 5Y14.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELTX Yearly Revenue VS EstimatesELTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2029 2030 2031 2032 5M 10M 15M 20M 25M
ELTX Yearly EPS VS EstimatesELTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ELTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELTX Price Earnings VS Forward Price EarningsELTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELTX Per share dataELTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

ELTX's earnings are expected to grow with 19.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.67%
EPS Next 3Y19.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELICIO THERAPEUTICS INC

NASDAQ:ELTX (11/28/2025, 8:25:46 PM)

9.36

+0.2 (+2.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners9.65%
Inst Owner Change33.94%
Ins Owners1.62%
Ins Owner Change0%
Market Cap163.71M
Revenue(TTM)N/A
Net Income(TTM)-54.61M
Analysts82.5
Price Target15.81 (68.91%)
Short Float %7.57%
Short Ratio8.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.39%
Min EPS beat(2)-2.76%
Max EPS beat(2)5.54%
EPS beat(4)1
Avg EPS beat(4)-24.55%
Min EPS beat(4)-86.68%
Max EPS beat(4)5.54%
EPS beat(8)2
Avg EPS beat(8)-30.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 83.39
P/tB 83.39
EV/EBITDA N/A
EPS(TTM)-3.15
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-2.15
FCFYN/A
OCF(TTM)-2.15
OCFYN/A
SpS0
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -184.95%
ROE -2977.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-129.24%
ROA(5y)-122.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 5.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -30.72%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.28
Altman-Z -11.47
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)10.91%
Cap/Depr(5y)98.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.83%
EPS Next Y34.67%
EPS Next 2Y24.67%
EPS Next 3Y19.38%
EPS Next 5Y14.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.43%
OCF growth 3YN/A
OCF growth 5YN/A

ELICIO THERAPEUTICS INC / ELTX FAQ

Can you provide the ChartMill fundamental rating for ELICIO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELTX.


What is the valuation status for ELTX stock?

ChartMill assigns a valuation rating of 0 / 10 to ELICIO THERAPEUTICS INC (ELTX). This can be considered as Overvalued.


Can you provide the profitability details for ELICIO THERAPEUTICS INC?

ELICIO THERAPEUTICS INC (ELTX) has a profitability rating of 0 / 10.


What is the expected EPS growth for ELICIO THERAPEUTICS INC (ELTX) stock?

The Earnings per Share (EPS) of ELICIO THERAPEUTICS INC (ELTX) is expected to grow by 34.67% in the next year.